GlassScriptPhysician profile
Adam Pinney
NPI 1639529290
$5,113.73
in general payments reported to CMS, 2019-2025
14 companies · $55.84 in 2025
The $55.84 reported for 2025 was less than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
See the full distribution for Sports Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.39 · 2020: $12.72 · 2021: $153 · 2022: $4,719 · 2023: $93.18 · 2024: $51.95 · 2025: $55.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $200.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $3,665.04 | 2022 | |
| Medwest Associates | $955.93 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $126.13 | 2021-2023 | Iovera, Zilretta, Exparel |
| Ferring Pharmaceuticals INC. | $106.65 | 2023-2025 | Euflexxa |
| Depuy Synthes Sales INC. | $63.85 | 2021-2023 | Orthovisc, Monovisc |
| Pacira Therapeutics, INC. | $43.58 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $31.70 | 2023 | Seglentis |
| Horizon Therapeutics Plc | $28.39 | 2019 | |
| Bioventus LLC | $19.99 | 2025 | Gelsyn-3 |
| Fidia Pharma USA INC. | $19.43 | 2021 | |
| Endo Pharmaceuticals INC. | $16.74 | 2022 | |
| Embody, INC. | $15.52 | 2022 | |
| My01 INC. | $12.00 | 2023 | My01 Continuous Compartmental Pressure Monitor |
| Orthofix Medical, INC. | $8.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Pinney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.